SEOM clinical guideline for treatment of kidney cancer (2019)
Uložené v:
| Názov: | SEOM clinical guideline for treatment of kidney cancer (2019) |
|---|---|
| Autori: | M. Lázaro, B. P. Valderrama, C. Suárez, G. de-Velasco, C. Beato, I. Chirivella, A. González-del-Alba, N. Laínez, M. J. Méndez-Vidal, J. A. Arranz |
| Prispievatelia: | Institut Català de la Salut, [Lázaro M] Medical Oncology Department, Complexo Hospitalario Universitario de Vigo, Estrada Clara Campoamor 341, 36213 Vigo, Pontevedra, Spain. [Valderrama BP] Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain. [Suárez C] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [de-Velasco G] Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. [Beato C] Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain. [Chirivella I] Medical Oncology Department, Hospital Clínico, Universidad de Valencia, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Zdroj: | RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía instname Scientia Scientia. Dipòsit d'Informació Digital del Departament de Salut CLINICAL & TRANSLATIONAL ONCOLOGY r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2020. |
| Rok vydania: | 2020 |
| Predmety: | Neoplasias renales, Other subheadings::Other subheadings::/therapy, Ensayos clínicos como asunto, Kidney, Medical Oncology, 03 medical and health sciences, 0302 clinical medicine, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias renales, Sociedades médicas, Humans, DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms, Societies, Medical, Cancer, Clinical Trials as Topic, HEALTH SURVEILLANCE::Health Surveillance of Health Services::Delivery of Health Care::Patient Care::Therapeutics::Practice Guidelines as Topic, VIGILANCIA SANITARIA::vigilancia sanitaria de los servicios de salud::prestación sanitaria::asistencia al paciente::terapéutica::guías de práctica clínica como asunto, Kidney Neoplasms, Oncología médica, 3. Good health, Otros calificadores::Otros calificadores::/terapia, Practice Guidelines as Topic, Ronyons - Càncer - Tractament, Protocols clínics, Immunotherapy, Guías de práctica clínica como asunto |
| Popis: | In this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent advances in molecular biology have allowed the subclassification of renal tumours into different histologic variants and may help to identify future prognostic and predictive factors. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. No adjuvant therapy has demonstrated a clear benefit in overall survival. Considering the whole population of patients with advanced disease, the combination of axitinib with either pembrolizumab or avelumab increase response rate and progression-free survival, compared to sunitinib, but a longer overall survival has only been demonstrated so far with the pembrolizumab combo. For patients with IMDC intermediate and poor prognosis, nephrectomy should not be considered mandatory. In this subpopulation, the combination of ipilimumab and nivolumab has also demonstrated a superior response rate and overall survival vs. sunitinib. In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC. |
| Druh dokumentu: | Article |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1699-3055 1699-048X |
| DOI: | 10.1007/s12094-019-02285-7 |
| Prístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s12094-019-02285-7.pdf https://pubmed.ncbi.nlm.nih.gov/31993962 http://hdl.handle.net/10668/15017 https://hdl.handle.net/11351/6315 https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4334 https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4334 https://hdl.handle.net/20.500.12530/61702 https://link.springer.com/article/10.1007/s12094-019-02285-7 https://pubmed.ncbi.nlm.nih.gov/31993962/ https://www.ncbi.nlm.nih.gov/pubmed/31993962 https://dialnet.unirioja.es/servlet/articulo?codigo=7254525 https://link.springer.com/content/pdf/10.1007/s12094-019-02285-7.pdf https://hdl.handle.net/10668/15017 |
| Rights: | CC BY |
| Prístupové číslo: | edsair.doi.dedup.....0820332550c9d005d5a9c2a5fc4f6c6d |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | In this article, we review de state of the art on the management of renal cell carcinoma (RCC) and provide recommendations on diagnosis and treatment. Recent advances in molecular biology have allowed the subclassification of renal tumours into different histologic variants and may help to identify future prognostic and predictive factors. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. No adjuvant therapy has demonstrated a clear benefit in overall survival. Considering the whole population of patients with advanced disease, the combination of axitinib with either pembrolizumab or avelumab increase response rate and progression-free survival, compared to sunitinib, but a longer overall survival has only been demonstrated so far with the pembrolizumab combo. For patients with IMDC intermediate and poor prognosis, nephrectomy should not be considered mandatory. In this subpopulation, the combination of ipilimumab and nivolumab has also demonstrated a superior response rate and overall survival vs. sunitinib. In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC. |
|---|---|
| ISSN: | 16993055 1699048X |
| DOI: | 10.1007/s12094-019-02285-7 |